Skip to the answer

Iohexol

Iohexol is an iodine-based contrast dye that makes X-ray and CT images clearer, and it is used in several imaging procedures: spinal, blood vessel, urinary, digestive tract, joint and body cavity imaging.

Brand names OmnipaqueOraltag
Drug class Radiographic Contrast Agent
Rx Forms 2
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 5 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

How we combine label and product data →
✓No current FDA shortage listed · checked Oct 2, 2026 🚨Recall on record · 2
Iohexol at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Iohexol (Omnipaque) is one of the most widely used contrast dyes; its iodine blocks X-rays, so blood vessels, the spine, the gut, joints and the urinary tract stand out on X-ray and CT. Most people tolerate it well, noticing at most nausea, headache, an odd taste after a blood vessel injection, or back stiffness after a spinal one. Watch for a serious allergic reaction, like trouble breathing or throat swelling; the boxed warning, which your care team checks, limits which strengths may go into the spine. Because it can also harm the kidneys and heart, tell staff beforehand about past contrast reactions, allergies, kidney disease, heart failure, thyroid problems and metformin.

Clinical pearls

  • If you take metformin, ask whether to pause it, since contrast plus weak kidneys can cause dangerous acid buildup.
  • Radioactive iodine thyroid scans or treatment should be avoided for up to 6 weeks afterward, so tell your thyroid doctor.
  • Drink plenty of fluids before and after an injection, as your care team advises, to help protect your kidneys.
  • Report rash, blisters or peeling even weeks later, since severe skin reactions can start from 1 hour to several weeks after.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Only the right iodine strength may be used for spinal (intrathecal) injections. Iohexol injection 140 mg iodine/mL and 350 mg iodine/mL must not be used for this purpose. Even an accidental injection of the wrong concentration into the spinal fluid can cause death, seizures, bleeding in the brain, coma, paralysis, arachnoiditis (inflammation around the spinal nerves), kidney failure, cardiac arrest, muscle breakdown, high body temperature and brain swelling.

This is a risk for the care team to prevent by checking the product before use. If you have a spinal procedure and feel suddenly unwell, tell staff immediately.

Read the full warning on DailyMed →
How you get itPrescription only
Comes asInjection, Oral solution
On the market since1985
Companies that make it9
FDA label last updatedApr 7, 2026
FDA’s strongest warning (boxed)Yes, read the warning

Patient information guide — a plain-language walkthrough of Iohexol, written from its FDA label.

What Iohexol is used for

▾

Iohexol is an imaging contrast agent with several product-specific uses.

  • Omnipaque and Iohexol injection (spinal): myelography and CT myelography, and CT cisternography, in adults and children 2 weeks and older.
  • Omnipaque and Iohexol injection (into arteries): heart ventriculography and aortography in adults and children, and pulmonary angiography in children.
  • Omnipaque and Iohexol injection (into arteries, adults): selective coronary, cerebral and peripheral arteriography, and intra-arterial digital subtraction angiography.
  • Omnipaque and Iohexol injection (into a vein): excretory urography and CT of the head and body in adults and children.
  • Omnipaque and Iohexol injection (into a vein, adults): peripheral venography and intravenous digital subtraction angiography.
  • Omnipaque and Iohexol injection (oral or rectal): GI tract X-ray examination, and CT of the abdomen and pelvis together with intravenous use.
  • Omnipaque and Iohexol injection (joint): arthrography in adults.
  • Omnipaque and Iohexol injection (body cavity): ERP and ERCP, herniography and hysterosalpingography in adults, and voiding cystourethrography in children.
  • Oraltag (oral): CT of the abdomen and pelvis to outline the bowel loops. It is not for diagnostic examination of the GI tract.

How Iohexol works

▾

Iohexol contains iodine, which blocks X-rays. The amount of X-ray blocking matches the amount of iohexol in the area. Because its concentration changes over time, it gives time-dependent contrast that helps show body structures. When taken by mouth, it outlines the bowel loops on CT.

Iohexol dosage

▾

The form, strength and amount depend on the procedure, your age, weight and health, and the equipment used. Your care team follows the label’s procedure-specific recommendations.

  • Injection products are given by trained staff into the spine, a blood vessel, a joint or a body cavity.
  • Oral products are swallowed. Some are also given rectally in children.
  • Oraltag is mixed with water or another beverage and taken 20 to 60 minutes before the scan.
  • Hydration before and after injection is advised.

Dosing details from the FDA-approved label

From the Iohexol prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Lumbar Myelography (intrathecal, adults)
    • 180 mg iodine/mL: 10 mL to 17 mL
    • 240 mg iodine/mL: 7 mL to 12.5 mL. Administer over 1 minute to 2 minutes
    • If repeat examinations are required, allow at least 48 hours for clearance; 5 days to 7 days is recommended whenever possible
  • Thoracic Myelography (intrathecal, adults)
    • 240 mg iodine/mL: 6 mL to 12.5 mL
    • 300 mg iodine/mL: 6 mL to 10 mL
    • If CT myelography is performed, delay imaging by several hours to reduce the degree of contrast
  • Cervical Myelography (intrathecal, adults)
    • Lumbar injection: 240 mg iodine/mL 6 mL to 12.5 mL, 300 mg iodine/mL 6 mL to 10 mL
    • C1-2 injection: 180 mg iodine/mL 7 mL to 10 mL, 240 mg iodine/mL 6 mL to 12.5 mL, 300 mg iodine/mL 4 mL to 10 mL
  • Total Columnar Myelography and CT Cisternography (intrathecal, adults)
    • Total columnar myelography: 240 mg iodine/mL 6 mL to 12.5 mL, 300 mg iodine/mL 6 mL to 10 mL
    • CT cisternography: 180 mg iodine/mL 10 mL to 17 mL, 240 mg iodine/mL 7 mL to 12.5 mL
  • Intra-arterial: Cardiac Ventriculography, Selective Coronary Arteriography, Aortography (adults)
    • Ventriculography 350 mg iodine/mL: 40 mL (Range of 30 mL to 60 mL)
    • Selective coronary arteriography 350: 5 mL (Range of 3 mL to 14 mL)
    • Aortic root and arch alone 350: 50 mL (Range of 20 mL to 75 mL)
    • Aortography/visceral 300: aorta 50 mL to 80 mL, abdominal aorta branches 30 mL to 60 mL, renal arteries 5 mL to 15 mL
    • Maximum: 250 mL for 350 mg iodine/mL; 290 mL for 300 mg iodine/mL
  • Intra-arterial: Cerebral and Peripheral Arteriography (adults)
    • Cerebral 300: common carotid 6 mL to 12 mL, internal carotid 8 mL to 10 mL, external carotid 6 mL to 9 mL, vertebral 6 mL to 10 mL
    • Aortofemoral runoffs 300: 30 mL to 90 mL, 350: 20 mL to 70 mL
    • Selective arteriogram 300: 10 mL to 60 mL, 350: 10 mL to 30 mL
    • Maximum: 290 mL for 300 mg iodine/mL; 250 mL for 350 mg iodine/mL
  • IA-DSA (head, neck, abdominal, renal, and peripheral vessels)
    • 140 mg iodine/mL: aorta 20 mL to 45 mL at 8 mL/sec to 20 mL/sec
    • Carotid 5 mL to 10 mL at 3 mL/sec to 6 mL/sec
    • Femoral 9 mL to 20 mL at 3 mL/sec to 6 mL/sec
    • Vertebral 4 mL to 10 mL at 2 mL/sec to 8 mL/sec
    • Renal 6 mL to 12 mL at 3 mL/sec to 6 mL/sec
    • Other aortic branches 8 mL to 25 mL at 3 mL/sec to 10 mL/sec
    • Maximum: 250 mL
  • Intravenous: Excretory Urography (adults)
    • 300 or 350 mg iodine/mL: 0.6 mL/kg to 1.2 mL/kg body weight
    • Maximum: 102 mL
    • Dose based on body weight
  • Intravenous: CT Head, CT Body, Peripheral Venography, IV-DSA (adults)
    • CT head: 240 mg iodine/mL 120 mL to 250 mL by infusion
    • 300: 70 mL to 150 mL by rapid injection
    • 350: 80 mL by rapid injection
    • CT body: 300: 50 mL to 200 mL
    • 350: 60 mL to 100 mL by rapid injection
    • Peripheral venography: 240: 20 mL to 150 mL per leg
    • 300: 40 mL to 100 mL per leg
    • IV-DSA 350: 30 mL to 50 mL at 7.5 mL/sec to 30 mL/sec using a pressure inject
    • Maximum: Maximum cumulative total dose for IV-DSA is 250 mL
    • Frequently three or more IV-DSA doses may be required
  • Oral radiographic examination of the GI tract (adults)
    • 50 mL to 100 mL of OMNIPAQUE injection 350 mg iodine/mL administered undiluted orally
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION For each imaging procedure, specific dosage forms, concentrations, and presentations are recommended. Individualize the concentration and volume according to the specific dosing tables and accounting for factors such as age, body weight, and condition of the patient, and the equipment and imaging technique used. ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 , 2.7 , 2.8 , 2.9 ) See full prescribing information for complete dosing and administration information. ( 2 ) 2.1 Important Dosage and Administration Instructions Specific dosage forms, concentrations, and presentations of OMNIPAQUE are recommended for each type of imaging procedure [see Dosage and Administration (2.2 , 2.3 , 2.4 , 2.5 , 2.6 , 2.7 , 2.8 , 2.9) and Warnings and Precautions (5.1 , 5.2) ]. Individualize the volume, strength, and rate of administration of OMNIPAQUE injection according to the specific dosing tables [see Dosage and Administration (2.2 , 2.3 , 2.4 , 2.5 , 2.6 , 2.7 , 2.8 , 2.9) ] . Consider factors such as age, body weight, vessel size, blood flow rate within the vessel, anticipated pathology, degree and extent of opacification required, structures or area to be examined, disease processes affecting the patient, and equipment and technique to be employed. Hydrate patients before and after administration of OMNIPAQUE injection [see Warnings and Precautions (5.4) ]. Use aseptic technique for all handling and administration of OMNIPAQUE injection. Administer OMNIPAQUE injection at either body (37°C, 98.6°F) or room temperature (20°C to 25°C, 68°F to 77°F). Do not mix OMNIPAQUE injection with, or inject in intravenous lines containing, other drugs or total nutritional admixtures except when OMNIPAQUE injection is administered in an automated contrast injection system or contrast management system suitable for simultaneous injection of OMNIPAQUE injection and 0.9% Sodium Chloride Injection [see Dosage and Administration (2.10 , 2.11) ]. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Each container of OMNIPAQUE injection and OMNIPAQUE oral solution in single-dose containers are intended for one procedure only. Discard any unused portion.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Iohexol side effects

▾

Common side effects

  • Headache, including after spinal (intrathecal) use
  • Back or neck pain and stiffness after spinal use
  • Nausea and vomiting
  • Diarrhea, stomach pain and gas after oral use
  • Pain, blurred vision or taste changes after injection into a vessel
  • Pain, swelling and a heat sensation at the injection site, such as in a joint or body cavity
  • Dizziness

When to get medical help

  • Get emergency help for trouble breathing, throat tightness, swelling of the face or throat, or a sudden severe allergic reaction.
  • Tell staff or seek care right away for chest pain, a fast or irregular heartbeat, or fainting.
  • Seek help for seizures, confusion, paralysis, or severe changes in alertness after a spinal injection.
  • Report a rash, blisters or skin peeling. These can start from 1 hour to several weeks after the injection.
  • Report pain, swelling or skin changes where the injection went in, which can be a sign of leakage into the tissue.
  • Tell your doctor if you pass much less urine than usual, because kidney injury can occur.
  • Babies and toddlers up to 3 years old may need thyroid monitoring after exposure.

Side effects depend on the route used.

  • Spinal: headache, back or neck pain, nausea, vomiting, dizziness.
  • Into an artery or vein: pain, blurred vision, taste changes, irregular heartbeats, chest pain, nausea.
  • Oral: diarrhea, nausea, vomiting, belly pain, gas, headache.
  • Joint or body cavity: pain, swelling and a heat sensation.

Seek urgent help for allergic reactions, breathing trouble, chest pain, seizures, severe skin reactions or sharply reduced urination.

Iohexol warnings and precautions

▾
  • Spinal use of the wrong iodine concentration can be fatal (boxed warning).
  • Serious allergic reactions can occur, including anaphylaxis.
  • Acute kidney injury can occur, especially with kidney disease, dehydration, diabetes, heart failure, advanced blood vessel disease, older age or multiple myeloma.
  • Heart and blood pressure reactions, including shock and cardiac arrest, can occur.
  • Blood clots can occur during angiocardiography. Leakage into tissue can cause damage.
  • Thyroid problems can occur, including thyroid storm in hyperthyroidism and low thyroid function in children up to 3 years.
  • Hypertensive crisis is possible with pheochromocytoma, and sickle cell crisis with sickle cell disease.
  • Severe skin reactions can appear from 1 hour to several weeks later.
  • Seizures can occur after spinal use.

Iohexol interactions

▾

Some medicines and tests are affected by iohexol.

  • Metformin: higher risk of lactic acidosis if kidney function worsens, so it may be stopped around the procedure.
  • Radioactive iodine: thyroid uptake may be reduced, so avoid thyroid therapy or testing for up to 6 weeks.
  • Protein-bound iodine test: results are affected for at least 16 days.
  • Seizure-threshold-lowering medicines: these may be stopped before and after a spinal injection.
  • Nephrotoxic or diuretic medicines: these add to kidney injury risk.

Interactions listed in the FDA-approved label

From the Iohexol prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Metformin: Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis in patients with renal impairment, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iohexol injection in patients with an eGFR between 30 and 60 mL/min/1.73 m2, a history of hepatic impairment, alcoholism or heart failure, or who will receive intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the procedure and reinstitute metformin only after renal function is stable.
  • Radioactive iodine (I-131 and I-123): Iohexol may interfere with thyroid uptake of radioactive iodine and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post iohexol injection.
  • Protein-bound iodine test: Iodinated contrast agents, including iohexol, will temporarily increase protein-bound iodine in blood. Do not perform protein-bound iodine test for at least 16 days following administration. Thyroid function tests not depending on iodine estimation, e.g., T3 resin uptake or direct thyroxine assays, are not affected.
Read the label’s full interactions text

7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iohexol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable. Radioactive Iodine Iohexol may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post iohexol injection. 7.2 Drug-Laboratory Test Interactions Protein-Bound Iodine Test Iodinated contrast agents, including iohexol, will temporarily increase protein-bound iodine in blood. Do not perform protein-bound iodine test for at least 16 days following administration of iohexol injection. However, thyroid function tests that do not depend on iodine estimation, e.g., T3 resin uptake or direct thyroxine assays, are not affected.

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Check Iohexol against a supplement or herb →

Before taking Iohexol

▾
  • Past reaction to contrast dye, asthma, or drug or food allergies.
  • Kidney problems, dehydration, diabetes, heart failure or advanced vascular disease.
  • Hyperthyroidism, a thyroid nodule, pheochromocytoma or sickle cell disease.
  • Pregnancy: hysterosalpingography is contraindicated during pregnancy or suspected pregnancy, menstruation, and with genital tract infection or known or suspected reproductive tract cancer.
  • Breastfeeding: stopping is not necessary, but you may pump and discard milk for 10 hours.
  • Children: safety varies by procedure, and children up to 3 years may need thyroid monitoring.
  • Older adults: reduced kidney function is more likely, so kidney monitoring may help.

Iohexol overdose

▾

Too much given into an artery or vein can be life-threatening. It mainly affects the lungs and heart. Symptoms include cyanosis (bluish skin), slow heartbeat, acidosis, lung bleeding, convulsions, coma and cardiac arrest. Treatment supports vital functions and treats symptoms. Iohexol can be removed by dialysis.

What Iohexol does in the body

▾

The amount of contrast depends on the iodine concentration. After intravenous or intra-arterial injection, iodine levels in the blood peak within 15 to 120 seconds. In the spine, contrast lasts at least 30 minutes for conventional imaging. It spreads upward over about 1 to 4 hours on CT. Swallowed iohexol outlines the GI tract.

How your body processes Iohexol

▾

Less than 1% of swallowed iohexol is absorbed from a normal gut. This may increase with bowel perforation or obstruction. After intravenous use, the half-life was about 12.6 hours. Iohexol is not significantly metabolized. It is removed unchanged by the kidneys, with about 90% of an intravenous dose cleared in 24 hours.

How to store Iohexol

▾

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) . stored in a contrast media warmer for up to one month, not to exceed 37°C (98. Store between 0°C and 30°C (32°F to 86°F).

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

Iohexol: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Iohexol — the kind of thing our pharmacy team would talk through with you at the counter.

What is iohexol used for?

▾
It is a contrast dye that makes X-rays and CT scans easier to read. Depending on the product, it can be used to look at the spine, blood vessels, urinary system, digestive tract, joints and body cavities. Oraltag is a drink used only for abdominal and pelvic CT.

How will I get it, and do I need to prepare?

▾
Staff will give it by injection or by mouth, depending on the scan. The label advises staying well hydrated before and after an injection. Oraltag is mixed with a drink and taken 20 to 60 minutes before your scan. Follow your imaging team’s instructions.

What side effects should I expect?

▾
They vary by route. After a spinal injection, headache, back pain and nausea are common. Swallowed forms often cause diarrhea, nausea or belly pain. Injection into a vessel can cause a warm feeling, pain, taste changes or blurred vision.

When should I get help right away?

▾
Get help for trouble breathing, throat or face swelling, chest pain, fainting, seizures, confusion or weakness. Also tell your care team about skin blisters or peeling, much less urine than normal, or pain and swelling at the injection site.

Do I need to stop my other medicines?

▾
Tell the team about everything you take. Metformin may need to be stopped around the procedure, especially with kidney issues. Some medicines that lower the seizure threshold may be stopped before a spinal injection.

Is it safe if I’m pregnant or breastfeeding?

▾
Hysterosalpingography with Omnipaque should not be done during pregnancy or suspected pregnancy. For breastfeeding, stopping is not necessary because the baby’s exposure is small. You may choose to pump and discard milk for 10 hours after an injection.

Is Iohexol available over the counter?

▾
Iohexol is dispensed by prescription according to its FDA labeling, so it isn't sold over the counter. Your prescriber and pharmacist will determine if it's appropriate for you.

When was Iohexol first available?

▾
Iohexol has been available in the United States since at least 1985, based on FDA approval history (Drugs@FDA) and product marketing records.

Who makes Iohexol?

▾
Iohexol is supplied by 9 manufacturers listed in the FDA NDC Directory, including GE Healthcare Inc., GE Healthcare, Amneal Pharmaceuticals Private Limited.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Iohexol on HelloPharmacist

🌿Drug & Supplement CheckerIohexol vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Iohexol NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Iohexol Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Iohexol forms and strengths (how it comes)

Iohexol is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Injection

By mouth · Into a joint · Into a vein · Into the fluid around the spinal cord · Intravascular · Rectal
Brands Omnipaque
How this form is used
What it may be used for
  • Omnipaque and Iohexol injection are used for imaging in adults and children, including spinal, blood vessel, urinary and CT imaging.
  • Omnipaque and Iohexol injection are also used for joint imaging (arthrography) in adults and body cavity imaging.
  • Omnipaque and Iohexol injection can be used by mouth or rectally for GI tract X-rays and for abdominal and pelvic CT, as listed on the label.
Important instructions
  • Omnipaque and Iohexol injection have specific strengths recommended for each type of procedure.
  • Omnipaque and Iohexol injection are single-dose containers for one procedure only. Unused portions are discarded.
  • Omnipaque and Iohexol injection should be given with hydration before and after the procedure.
Available strengths 5 strengths
140 mg/mL 180 mg/mL 240 mg/mL 300 mg/mL 350 mg/mL
49 FDA-listed product records ⓘ

Oral solution

By mouth
Brands Omnipaque Oraltag
How this form is used
What it may be used for
  • Oraltag is used for CT of the abdomen and pelvis to outline the bowel loops.
  • Oraltag is not indicated for diagnostic examination of the GI tract.
  • OMNIPAQUE oral solution is for oral use only.
Important instructions
  • Oraltag powder is mixed with water or another beverage just before use.
  • Oraltag is taken 20 to 60 minutes before imaging.
  • Oraltag prepared solution is protected from strong sunlight, and unused portions are discarded.
  • OMNIPAQUE oral solution comes in single-dose containers and is never given into a vein or artery.
Available strengths 4 strengths
9 mg/mL 12 mg/mL 4.5 g 1 kg/kg
8 FDA-listed product records ⓘ

Iohexol on the U.S. market: products, makers and brands

How Iohexol appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

9 companies list 61 Iohexol product records with the FDA, mostly as injection, oral solution; the earliest marketing or approval year on record is 1985. Brand names on the directory include Omnipaque, Oraltag; the rest are generics.

2
Dose forms ⓘ
9
Manufacturers
3
Brand names
61
FDA-listed product records ⓘ
1985
First marketed ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (4) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

GE Healthcare Inc.57%
GE Healthcare16%
Amneal Pharmaceuticals Private Limited13%
Divi's Laboratories Limited3%
Medical Purchasing Solutions, LLC3%
GE Healthcare Lindesnes2%
Other makers5%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Iohexol is used (Medicaid data)

A general measure of how commonly Iohexol is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Iohexol is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

580,886
Medicaid prescriptions filled (Q1–Q4 2025)
$36.7M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Iohexol prescribed? Of the 1,600 medications we measure, Iohexol ranks #248 by Medicaid prescriptions — more than 85% of them.

Where Iohexol ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #248 of 1,600
#243 Ethinyl Estradiol / No... 587,481 Rx #244 Clozapine 587,393 Rx #245 Ipratropium 583,555 Rx #246 Benzoyl Peroxide Topic... 583,362 Rx #247 Benzoyl Peroxide 583,362 Rx #248 Iohexol 580,886 Rx #249 Estradiol Transdermal... 575,018 Rx #250 Olopatadine Ophthalmic 567,428 Rx #251 Isosorbide 563,613 Rx #252 Morphine 562,550 Rx #253 Chlorthalidone 561,590 Rx

Utilization by Iohexol product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

Other Iohexol products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)

580,886 Medicaid prescriptions (Q1–Q4 2025) 100% of Iohexol prescriptions shown $36.7M gross reimbursement (before rebates) ≈ $63 per prescription (gross)

Summed across the 24 of 56 listed NDC products with Medicaid activity.

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Iohexol, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 24 of 56 listed Iohexol NDCs with Medicaid activity.

Compare Iohexol products

A representative set of FDA-listed product records for Iohexol — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 61 of 61 products — FDA National Drug Code Directory. See every product, package size and price: browse all 61 Iohexol NDCs →

Iohexol brand names

Iohexol is sold under 2 brand names in the FDA directory — Omnipaque, Oraltag. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Omnipaque Oraltag

Who makes Iohexol: manufacturers and labelers

9 companies list Iohexol products with the FDA. By number of product records, the largest are GE Healthcare Inc., GE Healthcare, Amneal Pharmaceuticals Private Limited. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

GE Healthcare Inc. 35 GE Healthcare 10 Amneal Pharmaceuticals Private Limited 8 Divi's Laboratories Limited 2 Medical Purchasing Solutions, LLC 2 GE Healthcare Lindesnes 1 Interpharma Praha, a.s. 1 Zhejiang Haizhou Pharmaceutical Co., Ltd. 1 Zhejiang Starry Pharmaceutical Co., Ltd. 1

Iohexol drug class (RxNorm)

Iohexol belongs to the Radiographic Contrast Agent class.

Pharmacologic class Radiographic Contrast Agent
Drug family (ATC) Watersoluble, nephrotropic, low osmolar X-ray contrast media
How it works X-Ray Contrast Activity

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Iohexol page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Apr 7, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Iohexol.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Iohexol after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
5
NDC products indexed
61
Distinct labelers/manufacturers represented
9
Linked representative label ⓘ
GE Healthcare Inc.
Linked label effective
Apr 7, 2026
Composite sections available
23
Linked SPL Set ID
eee15ebe-d349-4497-acef-6abe7a8247fb
Linked SPL Document ID
61f3e388-89bf-43d6-ad51-b620fff561fb
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. GE Healthcare Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →